# US 11,298,379 B2 · Compositions comprising milk fat globules and methods of making same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,298,379 B2 - Document ID: US11298379B2 - Status: Granted - Kind: B2 - Application number: 16/898,804 - Filed: 2020-06-11 - Published: 2021-10-21 - Granted: 2022-04-12 - Earliest claimed: 2020-04-16 - Applicants: James F. Kane - Inventors: James F. Kane - Web page: https://patentgrep.com/patent/US11298379B2 ## CPC - A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays} - A61K 35/20: Milk; Whey; Colostrum - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration} - A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} - A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)} - A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Compositions including anti-viral compositions, therapeutic compositions, sunscreen compositions, skin treatment compositions, anti-aging compositions, and methods of making the same, are provided. Each composition includes milk fat globules (MFG) and may contain one or more agents encapsulated by the MFG. The unique nature of MFG provides an intact mammalian membrane containing proteins, glycoproteins, and carbohydrates found in mammary cells. By treating an infected patient with MFG, the MFG serve as a surrogate cell and interact with enveloped viruses, such as the COVID-19 coronavirus, the Herpes virus, and the Epstein Barr Virus, rendering them non-infectious. MFG derived from mammals can also be used to deliver pharmaceutical materials into an animal body such that the pharmaceutical materials bypass the venous blood and enter directly into the animal's lymphatic system. MFG allow the delivery of materials orally that could not heretofore have been delivered efficiently. ## Claims ### Claim 1 A method for treating a viral infection in an oropharyngeal cavity of a patient, the viral infection being caused by an enveloped virus selected from the group consisting of SARS-CoV-2 coronavirus, Epstein Barr Virus (EBV), and Herpesviruses, wherein the enveloped virus (1) can be transmitted to another person through the oropharyngeal cavity, (2) uses a glycoprotein or ACE-2 protein in a cell membrane of a cell to initiate a binding event with the cell membrane, and (3) after the binding event, deposits viral genetic material inside the cell where the viral genetic material begins a replication process, the method comprising: preparing a gargle composition by separating milk fat globules from milk obtained from a mammalian source, and mixing the separated milk fat globules with a liquid carrier selected from the group consisting of water, milk, fruit juice, a sugar solution, a sports drink, tea, chilled coffee, a mouth wash, and an ethanol-based liquid, to form the gargle composition, the gargle composition consisting of from 16% by weight to 80% by weight milk fat globules and the liquid carrier, the milk fat globules comprising an organized mammalian membrane containing glycoproteins and ACE-2 protein; containing the gargle composition in a spray bottle; administering the gar composition by spraying the gargle composition from the spray bottle into the oropharyngeal cavity; and gargling with the gargle composition in the oropharyngeal cavity, the gargling comprising gargling at least twice over a ten-day period. ### Claim 2 (depends on 1) The method of claim 1, further comprising: testing a patient for a viral infection caused by SARS-CoV-2 coronavirus; determining from the testing that the patient is infected with SARS-CoV-2 coronavirus; and administering to the patient, the gargling with the gargle composition, within five days of the determining. ### Claim 3 (depends on 1) The method of claim 1, wherein the enveloped virus is SARS-CoV-2 coronavirus. ### Claim 4 (depends on 1) The method of claim 1, wherein the preparing comprises mixing liquid or powdered milk fat globules with the liquid carrier to form the gargle composition. ### Claim 5 (depends on 1) The method of claim 1, wherein the gargling further comprises gargling with the gargle composition for at least three seconds, and expelling the gargle composition after the gargling with the gargle composition. ### Claim 6 A method for treating a topical infection on skin, caused by an enveloped virus that binds with cell membranes containing heparin sulfate, the enveloped virus being selected from the group consisting of Herpesviruses, the method comprising: preparing an antiviral composition by separating milk fat globules from milk obtained from a mammalian source, and mixing the separated milk fat globules with a pharmaceutically acceptable topical carrier, the antiviral composition consisting of from 10% by weight to 95% by weight milk fat globules obtained from a mammalian source, based on the total weight of the antiviral composition, and from 5% by weight to 90% by weight the pharmaceutically acceptable topical carrier, based on the total weight of the antiviral composition, wherein the milk fat globules comprise an organized mammalian membrane containing glycoproteins, and the pharmaceutically acceptable topical carrier consists of petrolatum, paraben, mineral oil, hemp oil, full spectrum hemp oil, broad spectrum hemp oil, CBD, purified CBD, full spectrum hemp oil with CBDA/CBD at about a 1:1 ratio, beeswax, vitamin A, vitamin D, vitamin E, or a combination thereof; and applying, to the topical infection on the skin, the antiviral composition. ### Claim 7 (depends on 6) The method of claim 6, wherein the composition consists of from 25% by weight to 75% by weight milk fat globules, based on the total weight of the composition. ### Claim 8 (depends on 7) The method of claim 7, wherein the pharmaceutically acceptable topical carrier is petrolatum. ### Claim 9 (depends on 6) The method of claim 6, wherein the composition consists of from 40% by weight to 60% by weight milk fat globules from a mammalian source, based on the total weight of the composition, and from 60% by weight to 40% by weight the pharmaceutically acceptable topical carrier. ### Claim 10 (depends on 8) The method of claim 8, wherein the composition is in the form of a lip balm, the pharmaceutically acceptable carrier consists of petrolatum, the topical infection on the skin is an infection on lips, and the method comprises applying the lip balm to the topical infection on the lips. ### Claim 11 (depends on 6) The method of claim 6, wherein the composition is in the form of a spray and the method comprises spraying the composition on the topical infection on the skin. ### Claim 12 (depends on 9) The method of claim 9, wherein the composition is in the form of a salve and the method comprises applying the salve to the topical infection on the skin. ### Claim 13 (depends on 1) The method of claim 1, wherein the enveloped virus is SARS-CoV-2 coronavirus. ### Claim 14 (depends on 1) The method of claim 1, further comprising: testing a human for SARS-CoV-2 coronavirus; determining from the testing that the human is infected with SARS-CoV-2 coronavirus; and administering to the human, the gargling with the gargle composition, within three days of the determining. ### Claim 15 (depends on 1) The method of claim 1, wherein the enveloped virus is Epstein Barr Virus. ### Claim 16 (depends on 1) The method of claim 1, further comprising: testing a human for Epstein Barr Virus; determining from the testing that the human is infected with an Epstein Barr Virus infection; and administering to the human, the gargling with the gargle composition, within three days of the determining, wherein the gargling with the gargle composition comprises gargling with the gargle composition three times per day during an active stage of the Epstein Barr Virus infection. ### Claim 17 (depends on 16) The method of claim 16, wherein the gargling with the gargle composition comprises gargling with the gargle composition three times per day over several weeks. ### Claim 18 (depends on 1) The method of claim 1, wherein the enveloped virus is a Herpesvirus. ### Claim 19 (depends on 1) The method of claim 1, further comprising: testing a human for a Herpesvirus; determining from the testing that the human is infected with a Herpesvirus; and administering to the human, the gargling with the gargle composition, within three days of the determining. ### Claim 20 (depends on 6) The method of claim 6, wherein the Herpesvirus is selected from Herpes simplex virus type-1 (HSV-1), Herpes simplex virus type-2 (HSV-2), and Herpes Zoster virus (HZV).